Fortilin: A Potential Target for the Prevention and Treatment of Human Diseases.

Fortilin: A Potential Target for the Prevention and Treatment of Human Diseases.
复制标题

DOI:
10.1016/bs.acc.2017.06.006
复制
发表时间:
2017
影响因子:
--
通讯作者:
Fujise K
Fujise K
中科院分区:
医学2区
文献类型:
--
作者:
Pinkaew D;Fujise K

文献摘要

参考文献

被引文献

相似文献

Fortilin是一种高度保守的172个氨基酸的多肽,存在于细胞质、细胞核、线粒体、细胞外空间和循环血液中。它是一种多功能蛋白质,可保护细胞免于凋亡,促进细胞生长和细胞周期进程,结合钙(Ca2+),并具有抗病原体活性。它在人类和动物疾病发病机制中的作用也是多种多样的。Fortilin促进动脉粥样硬化的发展,促进全身和肺动脉高压,参与癌症的发展,并抑制糖尿病肾病。它对于胰腺β细胞响应肥胖和增加的胰岛素需求的适应性扩增、对于肝切除术后的肝脏再生以及对于保护肝脏免受酒精和ER应激诱导的损伤是重要的。Fortilin是体内细胞凋亡的一个可行的替代标记物,在脊椎动物胚胎和器官发育中起着关键作用。在鱼和虾中,Fortilin参与宿主防御细菌和病毒病原体。进一步的转化研究可以证明福替林是用于治疗各种人类疾病的可行的分子靶标,所述人类疾病包括但不限于动脉粥样硬化、高血压、某些肿瘤、糖尿病、糖尿病肾病、肝损伤以及异常免疫和宿主防御。
Fortilin is a highly conserved 172-amino-acid polypeptide found in the cytosol, nucleus, mitochondria, extracellular space, and circulating blood. It is a multifunctional protein that protects cells against apoptosis, promotes cell growth and cell cycle progression, binds calcium (Ca2+), and has anti-pathogen activities. Its role in the pathogenesis of human and animal diseases is also diverse. Fortilin facilitates the development of atherosclerosis, contributes to both systemic and pulmonary arterial hypertension, participates in the development of cancers, and worsens diabetic nephropathy. It is important for the adaptive expansion of pancreatic β-cells in response to obesity and increased insulin requirement, for the regeneration of liver after hepatectomy, and for protection of the liver against alcohol- and ER stress-induced injury. Fortilin is a viable surrogate marker for in vivo apoptosis, and it plays a key role in embryo and organ development in vertebrates. In fish and shrimp, fortilin participates in host defense against bacterial and viral pathogens. Further translational research could prove fortilin to be a viable molecular target for treatment of various human diseases including and not limited to atherosclerosis, hypertension, certain tumors, diabetes mellitus, diabetic nephropathy, hepatic injury, and aberrant immunity and host defense.
DOI: 10.1038/mt.2012.155
发表时间: 2012-12-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Baylot, Virginie;Katsogiannou, Maria;Rocchi, Palma
通讯作者: Rocchi, Palma
DOI: 10.1128/aac.45.8.2397-2399.2001
发表时间: 2001-08-01
影响因子: 4.9
作者:
Bhisutthibhan, J;Meshnick, SR
通讯作者: Meshnick, SR
DOI: 10.1016/j.fsi.2012.08.019
发表时间: 2013-04-01
影响因子: 4.7
作者:
Amparyup, Piti;Charoensapsri, Walaiporn;Tassanakajon, Anchalee
通讯作者: Tassanakajon, Anchalee
DOI: 10.1093/carcin/bgp022
发表时间: 2009-04-01
期刊: CARCINOGENESIS
影响因子: 4.7
作者:
Bazile, Franck;Pascal, Aude;Kubiak, Jacek Z.
通讯作者: Kubiak, Jacek Z.
DOI: 10.1016/s0304-3835(01)00753-4
发表时间: 2002-02-08
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Bai, YQ;Yamamoto, H;Yuasa, Y
通讯作者: Yuasa, Y